BioXcel Therapeutics Inc. (BTAI)
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
Merck to Complete Acquisition of Cidara Therapeutics
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
Compass Pathways - Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India